Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cannabidiolic Acid Complex
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Recipient : RS BioTherapeutics
Deal Size : $3.0 million
Deal Type : Financing
RS BioTherapeutics Secures $3 Million Seed II Round of Funding
Details : RSBT-001 is a patent-pending, nebulized, semi-synthetic, cannabidiolic acid complex in development to address exacerbation and prevent progression of both acute and chronic pulmonary inflammation related to respiratory diseases.
Brand Name : RSBT-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 26, 2022
Lead Product(s) : Cannabidiolic Acid Complex
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Recipient : RS BioTherapeutics
Deal Size : $3.0 million
Deal Type : Financing
Lead Product(s) : RSBT-001
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Recipient : RS BioTherapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The data from the proof-of-concept trial clearly indicates that RSBT-001, is a patent-pending, nebulized, semi-synthetic, cannabidiolic acid (CBDa) reduces cytokine level, and that this cytokine reduction is appropriately transient.
Brand Name : RSBT-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 11, 2022
Lead Product(s) : RSBT-001
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Recipient : RS BioTherapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : RSBT-001
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Recipient : RS BioTherapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
RS BioTherapeutics Enters Into License Agreement With Synthonics for First Investigational Compound
Details : Under the license agreement with Synthonics, Inc. for the exclusive, worldwide right for RS BioTherapeutic's lead compound, RSBT-001, as both an alternative and a complement to corticosteroids for the treatment of chronic obstructive pulmonary disease (C...
Brand Name : RSBT-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 23, 2022
Lead Product(s) : RSBT-001
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Recipient : RS BioTherapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?